6-(3-Chloro-2-fluorobenzyl)-1-[1(S)-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
| Title | Journal |
|---|---|
| Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA. | Bioorganic & medicinal chemistry 20160901 |
| Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. | Antimicrobial agents and chemotherapy 20150101 |
| Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase. | Journal of medicinal chemistry 20140424 |
| Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. | Antimicrobial agents and chemotherapy 20130601 |
| A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile. | Antiviral research 20130601 |
| Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles. | Journal of medicinal chemistry 20130214 |
| Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors. | Journal of inorganic biochemistry 20130101 |
| The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. | PLoS pathogens 20130101 |
| Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. | Retrovirology 20130101 |
| Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore. | Journal of medicinal chemistry 20121025 |
| Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). | Current opinion in pharmacology 20121001 |
| The future of integrase inhibitors of HIV-1. | Current opinion in virology 20121001 |
| The development of novel HIV integrase inhibitors and the problem of drug resistance. | Current opinion in virology 20121001 |
| Design, practical synthesis, and biological evaluation of novel 6-(pyrazolylmethyl)-4-quinoline-3-carboxylic acid derivatives as HIV-1 integrase inhibitors. | Molecules (Basel, Switzerland) 20120906 |
| Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations. | AIDS research and human retroviruses 20120901 |
| Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. | Journal of acquired immune deficiency syndromes (1999) 20120901 |
| The use of HIV-1 integrase inhibitors in antiretroviral naive patients. | Current opinion in HIV and AIDS 20120901 |
| Pharmacology of HIV integrase inhibitors. | Current opinion in HIV and AIDS 20120901 |
| Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. | Expert opinion on pharmacotherapy 20120901 |
| HIV integrase inhibitors in ART-experienced patients. | Current opinion in HIV and AIDS 20120901 |
| Tolerability of HIV integrase inhibitors. | Current opinion in HIV and AIDS 20120901 |
| [A single tablet against HIV: new combination preparation improves therapy]. | Deutsche medizinische Wochenschrift (1946) 20120801 |
| In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen. | Antiviral research 20120701 |
| The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet. | Expert opinion on investigational drugs 20120701 |
| Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? | Medicinal research reviews 20120701 |
| Update on raltegravir and the development of new integrase strand transfer inhibitors. | Southern medical journal 20120701 |
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. | Lancet (London, England) 20120630 |
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. | Lancet (London, England) 20120630 |
| Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. | Journal of biomolecular screening 20120601 |
| A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315 |
| Elvitegravir: a once-daily inhibitor of HIV-1 integrase. | Expert opinion on investigational drugs 20120301 |
| Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors. | Journal of chemical information and modeling 20120227 |
| In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. | Antiviral research 20120201 |
| Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. | The Lancet. Infectious diseases 20120101 |
| Elvitegravir: a once daily alternative to raltegravir. | The Lancet. Infectious diseases 20120101 |
| Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. | Expert review of anti-infective therapy 20120101 |
| Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond. | Current medicinal chemistry 20120101 |
| Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. | HIV/AIDS (Auckland, N.Z.) 20120101 |
| The use of preexposure treatments for HIV prophylaxis. | HIV/AIDS (Auckland, N.Z.) 20120101 |
| Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. | Intervirology 20120101 |
| Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. | Clinical & developmental immunology 20120101 |
| BF integrase genes of HIV-1 circulating in São Paulo, Brazil, with a recurrent recombination region. | PloS one 20120101 |
| Novel therapeutic strategies targeting HIV integrase. | BMC medicine 20120101 |
| Antiretroviral drugs: critical issues and recent advances. | Indian journal of pharmacology 20120101 |
| Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. | PloS one 20120101 |
| In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors. | Advances in virology 20120101 |
| Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. | PloS one 20120101 |
| Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. | Journal of medicinal chemistry 20111222 |
| The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. | The Journal of antimicrobial chemotherapy 20111201 |
| Recent advances in antiretroviral treatment and prevention in HIV-infected patients. | Current opinion in HIV and AIDS 20111201 |
| HIV-1 integrase inhibitors: a review of their chemical development. | Antiviral chemistry & chemotherapy 20111117 |
| 3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1. | Expert opinion on therapeutic patents 20111101 |
| Synthesis and biological evaluation of HQCAs with aryl or benzyl substituents on N-1 position as potential HIV-1 integrase inhibitors. | Bioorganic & medicinal chemistry 20110915 |
| Structural modifications of quinolone-3-carboxylic acids with anti-HIV activity. | Bioorganic & medicinal chemistry 20110815 |
| Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors. | Molecules (Basel, Switzerland) 20110811 |
| New first and second generation inhibitors of human immunodeficiency virus-1 integrase. | Expert opinion on therapeutic patents 20110801 |
| Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. | Antiviral research 20110801 |
| Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. | AIDS (London, England) 20110601 |
| Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study. | Journal of molecular graphics & modelling 20110601 |
| HIV-1 integrase inhibitor resistance and its clinical implications. | The Journal of infectious diseases 20110501 |
| Foamy virus biology and its application for vector development. | Viruses 20110501 |
| Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. | Clinical pharmacokinetics 20110401 |
| Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. | The Journal of antimicrobial chemotherapy 20110401 |
| Clinical management of HIV drug resistance. | Viruses 20110401 |
| Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. | AIDS (London, England) 20110327 |
| Allosteric inhibitor development targeting HIV-1 integrase. | ChemMedChem 20110207 |
| In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. | Antimicrobial agents and chemotherapy 20110201 |
| HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation. | European journal of medicinal chemistry 20110201 |
| 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors. | Bioorganic & medicinal chemistry letters 20110115 |
| Recent advances in antiretroviral drugs. | Expert opinion on pharmacotherapy 20110101 |
| K70Q adds high-level tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism. | PloS one 20110101 |
| Driving a decade of change: HIV/AIDS, patents and access to medicines for all. | Journal of the International AIDS Society 20110101 |
| HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients. | Virology journal 20110101 |
| Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. | AIDS research and treatment 20110101 |
| Patterns of resistance development with integrase inhibitors in HIV. | Infection and drug resistance 20110101 |
| HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. | PloS one 20110101 |
| G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. | Retrovirology 20110101 |
| A crystal structure of the catalytic core domain of an avian sarcoma and leukemia virus integrase suggests an alternate dimeric assembly. | PloS one 20110101 |
| Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements. | PloS one 20110101 |
| In-silico Comparative Study and Quantitative Structure-activity Relationship Analysis of Some Structural and Physiochemical Descriptors of Elvitegravir Analogs. | Journal of young pharmacists : JYP 20110101 |
| Role of raltegravir in the management of HIV-1 infection. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects. | Acta naturae 20110101 |
| Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. | Viruses 20101201 |
| Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors. | Viruses 20101201 |
| Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. | Journal of acquired immune deficiency syndromes (1999) 20101101 |
| Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. | The Journal of antimicrobial chemotherapy 20101101 |
| Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. | The Journal of antimicrobial chemotherapy 20101101 |
| Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: an overview. | Mini reviews in medicinal chemistry 20101001 |
| Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors. | Biochemistry 20100928 |
| HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. | AIDS (London, England) 20100910 |
| Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. | Drugs 20100910 |
| Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. | Journal of virology 20100901 |
| Novel integrase inhibitors for HIV. | Expert opinion on investigational drugs 20100901 |
| Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription. | PLoS pathogens 20100901 |
| Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20100801 |
| Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. | Virology 20100705 |
| Tautomerism and magnesium chelation of HIV-1 integrase inhibitors: a theoretical study. | ChemMedChem 20100705 |
| Resistance to integrase inhibitors. | Viruses 20100701 |
| HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. | The Journal of antimicrobial chemotherapy 20100601 |
| Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. | Biochemistry 20100504 |
| Retrovirus Integrase-DNA Structure Elucidates Concerted Integration Mechanisms. | Viruses 20100501 |
| Natural polymorphisms of integrase among HIV type 1-infected South African patients. | AIDS research and human retroviruses 20100401 |
| Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. | The Journal of infectious diseases 20100315 |
| Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. | Clinical pharmacology and therapeutics 20100301 |
| Single-tablet Quad regimen achieves high rate of virologic suppression. | AIDS patient care and STDs 20100301 |
| Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. | Journal of acquired immune deficiency syndromes (1999) 20100201 |
| Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. | Antiviral research 20100101 |
| Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. | Antiviral research 20100101 |
| Integrase inhibitors: a novel class of antiretroviral agents. | The Annals of pharmacotherapy 20100101 |
| Improving first-line antiretroviral therapy in resource-limited settings. | Current opinion in HIV and AIDS 20100101 |
| Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil. | AIDS research and human retroviruses 20100101 |
| Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. | Retrovirology 20100101 |
| [Analysis of HIV-1 integrase gene polymorphism in an HIV-infected population from the nosocomial outbreak of HIV infection in the south of Russia in 1989]. | Voprosy virusologii 20100101 |
| The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. | PloS one 20100101 |
| 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - clinical sciences. | Journal of the International AIDS Society 20100101 |
| Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. | Retrovirology 20100101 |
| Resistance to HIV-1 integrase inhibitors: A structural perspective. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20100101 |
| Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. | Retrovirology 20100101 |
| Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. | Retrovirology 20100101 |
| The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide element. | PloS one 20100101 |
| Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy. | Infection and drug resistance 20100101 |
| Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes. | Journal of virological methods 20091101 |
| Efavirenz: a decade of clinical experience in the treatment of HIV. | The Journal of antimicrobial chemotherapy 20091101 |
| Integrase inhibitors in salvage therapy regimens for HIV-1 infection. | Current opinion in HIV and AIDS 20091101 |
| Resistance to novel drug classes. | Current opinion in HIV and AIDS 20091101 |
| Elvitegravir: a new HIV integrase inhibitor. | Antiviral chemistry & chemotherapy 20091019 |
| In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer. | Future medicinal chemistry 20091001 |
| Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. | ChemMedChem 20090901 |
| Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. | Journal of medicinal chemistry 20090813 |
| Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. | Medical microbiology and immunology 20090801 |
| Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance. | Bioorganic & medicinal chemistry 20090701 |
| Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. | Journal of acquired immune deficiency syndromes (1999) 20090501 |
| [New antiretroviral drug classes in HIV therapy]. | MMW Fortschritte der Medizin 20090430 |
| Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. | Antimicrobial agents and chemotherapy 20090301 |
| Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. | AIDS research and human retroviruses 20090301 |
| Data demonstrate pharmacokinetic boosting activity of GS 9350. | AIDS patient care and STDs 20090301 |
| Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant. | Biochemistry 20090224 |
| New approaches for inhibiting HIV integrase: a journey beyond the active site. | Current opinion in investigational drugs (London, England : 2000) 20090201 |
| Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. | Current opinion in investigational drugs (London, England : 2000) 20090201 |
| Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. | Clinical pharmacology and therapeutics 20090101 |
| Emerging pharmacology: inhibitors of human immunodeficiency virus integration. | Annual review of pharmacology and toxicology 20090101 |
| Novel targets for antiretroviral therapy: clinical progress to date. | Drugs 20090101 |
| Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors. | Retrovirology 20090101 |
| Characterization and structural analysis of HIV-1 integrase conservation. | AIDS reviews 20090101 |
| Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. | Antiviral therapy 20090101 |
| Novel compounds for the treatment of HIV type-1 infection. | Antiviral chemistry & chemotherapy 20090101 |
| Drug interactions with new and investigational antiretrovirals. | Clinical pharmacokinetics 20090101 |
| Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. | Therapeutics and clinical risk management 20090101 |
| Pharmacotherapy of pediatric and adolescent HIV infection. | Therapeutics and clinical risk management 20090101 |
| Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. | Retrovirology 20090101 |
| Raltegravir: The evidence of its therapeutic value in HIV-1 infection. | Core evidence 20090101 |
| Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. | Journal of medicinal chemistry 20081225 |
| Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. | Antiviral research 20081101 |
| HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. | The Journal of antimicrobial chemotherapy 20081101 |
| [Resistance to integrase inhibitors]. | Enfermedades infecciosas y microbiologia clinica 20081101 |
| Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. | Journal of acquired immune deficiency syndromes (1999) 20081001 |
| Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. | AIDS (London, England) 20080912 |
| Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. | Biochemistry 20080909 |
| Emerging antiviral drugs. | Expert opinion on emerging drugs 20080901 |
| Phase III trial begins for elvitegravir. | AIDS patient care and STDs 20080901 |
| Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors. | Journal of medicinal chemistry 20080828 |
| Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. | Antimicrobial agents and chemotherapy 20080801 |
| Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. | AIDS research and human retroviruses 20080701 |
| Integrase inhibitors: a clinical review of raltegravir and elvitegravir. | Journal of HIV therapy 20080601 |
| A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series. | Bioorganic & medicinal chemistry letters 20080501 |
| Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. | Current opinion in HIV and AIDS 20080501 |
| Raltegravir: first in class HIV integrase inhibitor. | Therapeutics and clinical risk management 20080401 |
| Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. | Journal of medicinal chemistry 20080313 |
| Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). | Journal of virology 20080101 |
| Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. | Pharmacotherapy 20080101 |
| HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. | AIDS reviews 20080101 |
| Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies. | Journal of addictive diseases 20080101 |
| Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. | Retrovirology 20080101 |
| Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses. | Antiviral chemistry & chemotherapy 20080101 |
| Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir. | Positively aware : the monthly journal of the Test Positive Aware Network 20080101 |
| Integrase and integration: biochemical activities of HIV-1 integrase. | Retrovirology 20080101 |
| Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. | Antiviral therapy 20080101 |
| Raltegravir in the management of HIV-infected patients. | Drug design, development and therapy 20080101 |
| Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. | Bioorganic & medicinal chemistry letters 20071115 |
| Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion. | Journal of natural products 20071101 |
| Antiviral drugs in the treatment of AIDS: what is in the pipeline ? | European journal of medical research 20071015 |
| Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. | Journal of acquired immune deficiency syndromes (1999) 20071001 |
| Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. | Journal of acquired immune deficiency syndromes (1999) 20070701 |
| In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. | Retrovirology 20070101 |
| Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. | Retrovirology 20070101 |
| Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. | Journal of acquired immune deficiency syndromes (1999) 20060901 |
| Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. | Journal of medicinal chemistry 20060309 |
| MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline. | BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20060101 |
| Integrase inhibitors to treat HIV/AIDS. | Nature reviews. Drug discovery 20050301 |
| Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. | Science (New York, N.Y.) 20000128 |